BOSTON, MA -- (Marketwired) -- 11/14/13 -- The pharmaceutical industry, especially Big Pharma, has dramatically shifted…
Continue ReadingTag: tufts-center-for-the-study-of-drug-development
Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically According to the Tufts Center for the Study of Drug Development
Large Molecules Currently Represent a Dominant Share of Sales
Continue ReadingDrug Sponsors and Their External Service Partners Say Adjusting Relationship Models Offers a Path to Greater Performance and Efficiency, According to Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 10/08/13 -- While drug sponsor use of strategic relationships with contract…
Continue ReadingClinical Study Failures Vary Widely by Phase of Study and Therapeutic Class, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 09/10/13 -- While lack of commercial viability is the leading cause…
Continue ReadingDrug Industry Leaders See Collaboration as Key to Greater Productivity, According to Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 08/13/13 -- Responding to a widely shared need to improve the…
Continue ReadingCompanion Diagnostics, Key to Development of Personalized Medicines, Face Hurdles, According to Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwire) -- 01/24/13 -- Companion diagnostics, which are central to the creation of…
Continue ReadingNew Research From Tufts Center for the Study of Drug Development Characterizes Effectiveness and Variability of Patient Recruitment and Retention Practices
BOSTON, MA -- (Marketwire) -- 01/15/13 -- While nine out of 10 clinical trials worldwide meet…
Continue ReadingDrug Developers Need to More Fully Identify and Address Root Causes of R&D Inefficiency, According to Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwire) -- 01/08/13 -- While patent expirations on many top selling medicines are…
Continue Reading